AT Impf
6
47M
2
0.67
1
- Stages of investment
- Areas of investment
Summary
The main department of described Corporate Investor is located in the Munich. The company was established in Europe in Germany.
The important activity for fund was in 2014. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in less than 2 investment rounds annually.
Among the most successful fund investment fields, there are Biotechnology, Therapeutics. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Germany. Among the various public portfolio startups of the fund, we may underline Isarna Therapeutics Moreover, a startup needs to be at the age of 16-20 years to get the investment from the fund.
The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the AT Impf, startups are often financed by Wellington Partners, MIG AG, dievini Hopp Biotech Holding. The meaningful sponsors for the fund in investment in the same round are dievini Hopp Biotech Holding, Wellington Partners, MIG AG. In the next rounds fund is usually obtained by dievini Hopp Biotech Holding, Wellington Partners, Amgen.
Investments analytics
Analytics
- Total investments
- 6
- Lead investments
- 0
- Exits
- 1
- Follow on index
- 0.67
- Investments by industry
- Medical (6)
- Therapeutics (6)
- Biotechnology (6)
- Investments by region
-
- Germany (6)
- Peak activity year
- 2014
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 23
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| immatics biotechnologies | 21 Sep 2010 | Biotechnology, Medical, Therapeutics | Late Stage Venture | 63M | Germany, Baden-Württemberg, Germany |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.